These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26085373)

  • 1. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
    Kalathur M; Toso A; Chen J; Revandkar A; Danzer-Baltzer C; Guccini I; Alajati A; Sarti M; Pinton S; Brambilla L; Di Mitri D; Carbone G; Garcia-Escudero R; Padova A; Magnoni L; Tarditi A; Maccari L; Malusa F; Kalathur RK; A Pinna L; Cozza G; Ruzzene M; Delaleu N; Catapano CV; Frew IJ; Alimonti A
    Nat Commun; 2015 Jun; 6():7227. PubMed ID: 26085373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
    Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
    Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
    Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
    Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CK2 and PML: regulating the regulator.
    Lallemand-Breitenbach V; de Thé H
    Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
    Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
    Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.
    Hubackova S; Novakova Z; Krejcikova K; Kosar M; Dobrovolna J; Duskova P; Hanzlikova H; Vancurova M; Barath P; Bartek J; Hodny Z
    Cell Cycle; 2010 Aug; 9(15):3085-99. PubMed ID: 20699642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.
    Zhao T; Jia H; Li L; Zhang G; Zhao M; Cheng Q; Zheng J; Li D
    Oncol Rep; 2013 Jul; 30(1):377-84. PubMed ID: 23595577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
    Di Mitri D; Toso A; Chen JJ; Sarti M; Pinton S; Jost TR; D'Antuono R; Montani E; Garcia-Escudero R; Guccini I; Da Silva-Alvarez S; Collado M; Eisenberger M; Zhang Z; Catapano C; Grassi F; Alimonti A
    Nature; 2014 Nov; 515(7525):134-7. PubMed ID: 25156255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F; Huang X; Wu M; Gou S; Hu W
    Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
    Frappier L
    Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.
    Zhu D; Hensel J; Hilgraf R; Abbasian M; Pornillos O; Deyanat-Yazdi G; Hua XH; Cox S
    Mol Cell Biochem; 2010 Jan; 333(1-2):159-67. PubMed ID: 19629644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
    Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
    Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.
    Drygin D; Ho CB; Omori M; Bliesath J; Proffitt C; Rice R; Siddiqui-Jain A; O'Brien S; Padgett C; Lim JK; Anderes K; Rice WG; Ryckman D
    Biochem Biophys Res Commun; 2011 Nov; 415(1):163-7. PubMed ID: 22027148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.
    Intemann J; Saidu NE; Schwind L; Montenarh M
    Cell Signal; 2014 Jul; 26(7):1567-75. PubMed ID: 24686080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of protein kinase CK2 facilitates cellular senescence by inhibiting the expression of HO-1 in articular chondrocytes.
    Kim KM; Sohn DH; Kim K; Park YC
    Int J Mol Med; 2019 Feb; 43(2):1033-1040. PubMed ID: 30535443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retinoblastoma protein and PML collaborate to organize heterochromatin and silence E2F-responsive genes during senescence.
    Talluri S; Dick FA
    Cell Cycle; 2014; 13(4):641-51. PubMed ID: 24351540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intracellular domain of L1CAM binds to casein kinase 2α and is neuroprotective via inhibition of the tumor suppressors PTEN and p53.
    Wang Y; Schachner M
    J Neurochem; 2015 Jun; 133(6):828-43. PubMed ID: 25727698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.